TPWA
IMGN

TRUE Private Wealth Advisors’s Immunogen Inc IMGN Stock Holding History

TRUE Private Wealth Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-45
Closed -$426 – 964
2018
Q3 		$426 Buy
+45
New +$433 ﹤0.01% 1089

Other funds holding IMGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

TRUE Private Wealth Advisors's IMGN Position: Q4 2018 in Review

TRUE Private Wealth Advisors sold out of Immunogen Inc (IMGN) in Q4 2018, closing a stake of 45 shares — an estimated $426 sold.

TRUE Private Wealth Advisors first reported a position in IMGN in Q3 2018 and held it in 1 quarter. The position peaked at $426 in Q3 2018. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2018.

  • TRUE Private Wealth Advisors reported no remaining Immunogen Inc position as of Q4 2018 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 45 Immunogen Inc shares in Q4 2018, an estimated $426.
  • TRUE Private Wealth Advisors first reported a position in Immunogen Inc in Q3 2018 and held it in 1 quarter.
  • TRUE Private Wealth Advisors's Immunogen Inc position peaked at $426 in Q3 2018.
  • 200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2018.

Based on TRUE Private Wealth Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.